Recursion Pharmaceuticals (RXRX) reported a loss of 50 cents per share in the first quarter of 2025, wider than the Zacks Consensus Estimate of a loss of 44 cents. The company had incurred a loss of 39 cents per share in the year-ago quarter.In the absence of an approved product, Recursion Pharmaceuticals only recognizes collaboration and grant revenues from its partners. Total revenues in the reported quarter amounted to $14.7 million, up 7% year over year, primarily driven by the timing of projects from R ...